Clopidogrel, prasugrel and ticagrelor in adults with acute coronary syndrome: a review of the clinical effectiveness, cost effectiveness and guidelines
CADTH
Record ID 32012000686
English
Authors' recommendations:
While combination therapy with clopidogrel and ASA remains the basis of antiplatelet therapy in acute coronary syndrome (ACS) patients, each combined therapy of P2Y12 inhibitors (clopidogrel, prasugrel, or ticagrelor) and ASA can be considered for some groups depending on the clinical presentation and subsequent management for patients with ACS.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.cadth.ca/media/pdf/htis/june-2012/RC0360%20Antiplatelets%20for%20ACS%20Final.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Platelet Aggregation Inhibitors
- Ticlopidine
- Thiophenes
- Piperazines
- Purinergic P2Y Receptor Antagonists
- Adenosine
- Cost-Benefit Analysis
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.